8
ì −SSCG 20122012.3 Standard Protocol Project

StandardProtocol Project · ü.8,7+ % F β 2 2< 5 Effectof intravenousβ-2 agonisttreatmenton clinicaloutcomesin acute respiratorydistresssyndrome (BALTI-2): a multicentre, randomisedcontrolledtrial.Lancet

  • Upload
    others

  • View
    0

  • Download
    0

Embed Size (px)

Citation preview

Page 1: StandardProtocol Project · ü.8,7+ % F β 2 2< 5 Effectof intravenousβ-2 agonisttreatmenton clinicaloutcomesin acute respiratorydistresssyndrome (BALTI-2): a multicentre, randomisedcontrolledtrial.Lancet

ì

�������−SSCG 2012������������−

2012.3 ���� ��

Standard Protocol Project

�������������� �������

Page 2: StandardProtocol Project · ü.8,7+ % F β 2 2< 5 Effectof intravenousβ-2 agonisttreatmenton clinicaloutcomesin acute respiratorydistresssyndrome (BALTI-2): a multicentre, randomisedcontrolledtrial.Lancet

Essence

�+$�*�!%��- ����2#����

ü .�')/"�0&��(�

ü ���� $�!%

→�����1��surviving sepsis campaign guideline 2012�����!%�,��

Standard Protocol Project

�������������� �������

Page 3: StandardProtocol Project · ü.8,7+ % F β 2 2< 5 Effectof intravenousβ-2 agonisttreatmenton clinicaloutcomesin acute respiratorydistresssyndrome (BALTI-2): a multicentre, randomisedcontrolledtrial.Lancet

1D<8=6E

><�8=I)��33J� �1) �H�:*2) .AB-�#D9(K0%3) +'������.AB�-�4) D&�����H> 4mmol/L

→4F9�30 mL/kg�-�

63J� �5)MAPL65mmHg�?7�2&$-�6) G9C;, D&���/@��

or "5�H�L4mmol/L→CVP�ScvO2�:*��

7) "5�H��2���!:*

SURVIVING SEPSIS CAMPAIGNBUNDLES

�������������� �������

Page 4: StandardProtocol Project · ü.8,7+ % F β 2 2< 5 Effectof intravenousβ-2 agonisttreatmenton clinicaloutcomesin acute respiratorydistresssyndrome (BALTI-2): a multicentre, randomisedcontrolledtrial.Lancet

�#*&

ü �+� �-�34mmol/L�!)�����'$���#*&�,�

• CVP 2 8412mmHg0� ����12�15mmHg1• MAP ≧ 65mmHg• �. ≧ 0.5ml/kg/hr• ScvO2 ≧ 70% or SvO2≧65%• �-�%�0�-�10%���%�ScvO2≧70/�"$���(������1�1

�1 Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial.JAMA, 2010 Feb 24;303(8):739-46

Standard Protocol Project

�������������� �������

Page 5: StandardProtocol Project · ü.8,7+ % F β 2 2< 5 Effectof intravenousβ-2 agonisttreatmenton clinicaloutcomesin acute respiratorydistresssyndrome (BALTI-2): a multicentre, randomisedcontrolledtrial.Lancet

eP/e\

3LePlKcP≧30ml/kgü 2=h200kDa�d��HES�Q��������

jHM�-Q���HES�2=h70kDa����-��!"*#�

130kDa���� �$'�)��Ib� ���k

ü KcP�<h�@a�;7���(%&)�-Q�ZD��

ü \]6C�G8��i�fluid challenge�XY� ��

e\lHb7.0�9.0g/dl�UO�e\�]�ü [\A?RB�+gWV�7,S���;7��/4�fD��

ü .`T�EF�5��;7���1:9=�_0�ZD��

ü E^J��\>N≧50000/mm3�UO���

Standard Protocol Project

�������������� �������

Page 6: StandardProtocol Project · ü.8,7+ % F β 2 2< 5 Effectof intravenousβ-2 agonisttreatmenton clinicaloutcomesin acute respiratorydistresssyndrome (BALTI-2): a multicentre, randomisedcontrolledtrial.Lancet

"!84

ü 1#*.CK6ml/kgI�1�BJ

ü .@�$≦30cmH2O

ü 3.;D-�� PEEP�)&

ü G/'�A9=6⇒��������ü HPEEP >�PEEPI PF raitio≦200�ARDS J

ü �������ARDS(:���E?0�>�Comparison of Two Fluid-Management Strategies in Acute Lung InjuryN Engl J Med 2006; 354:2564-2575

ü .8,7+���%�F��β2 2<��5��Effect of intravenous β-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre,

randomised controlled trial. Lancet. 2012 Jan 21;379(9812):229-35.

Standard Protocol Project

�������������� �������

Page 7: StandardProtocol Project · ü.8,7+ % F β 2 2< 5 Effectof intravenousβ-2 agonisttreatmenton clinicaloutcomesin acute respiratorydistresssyndrome (BALTI-2): a multicentre, randomisedcontrolledtrial.Lancet

\rxq

�.-:�*;+9=

�.�1,29=or

�..#4;!=

3.*3%5=

MAP≧65mmHg

w?�d!!

�����U�H���VS��…

üMAP@j�-:�*;+9=o��ut��.#4;!=0.03QE/J��M�����∵!7'��ez��`~��.#4;!=�vZt�lC����

*3%5=�cB�}bü PJ��n[�F]k�ü PJ��xIs� �K�MAP�{e������y|F�m�ez��

ü �H�ut�*/5=Gs�fW����∵��_Ah��9"����� N Engl J Med 2010; 362:779-789

�.�K��n jUL������Na�XY���VS����0*< :&$=200mg/i

ü PH≥7.15�`~���Na�XYO�ut ��p�+)9�6�cB������∵D��!*>!"�Z���p�cB��( 85=R^_�gT���

Standard Protocol Project

�������������� �������

Page 8: StandardProtocol Project · ü.8,7+ % F β 2 2< 5 Effectof intravenousβ-2 agonisttreatmenton clinicaloutcomesin acute respiratorydistresssyndrome (BALTI-2): a multicentre, randomisedcontrolledtrial.Lancet

1EF/GB/!

ü 5& 14I6'�1EF�CLD@�0���∵0��14IH��9�8 <�7.6%���3��

Duration of hypotension prior to initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;34:1589-96.

ü GB%≦180mg/dl�A7��∵GB%≦110mg/dl -(�����?:��"GB M,�

N���.�/(���Intensive versus Conventional Glucose Control in Critically Ill PatientsThe NICE-SUGAR Study InvestigatorsN Engl J Med 2009;

360:1283-1297

ü ����;> �J���H2)+#21F����������K*F�$=��

Standard Protocol Project

�������������� �������